← All Sponsors
SPONSOR

Institut de Recherches Internationales Servier

Total Trials
2
Recruiting
2
Phases
Phase 1, Phase 2, Phase 3
Conditions studied: Epileptic EncephalopathyHypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)Myelodysplastic Syndromes (MDS)
NCT07227857 Phase 1, Phase 2
Recruiting

A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy

Epileptic Encephalopathy
United States, France, Italy View Trial →
NCT06465953 Phase 3
Recruiting

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)
United States, Australia, Brazil View Trial →